Benefits Canada

Head to head: Should psychedelics be used in the treatment of mental-health conditions?

Hallucinogens like ecstasy and magic mushrooms are being used in the treatment of depression and post-traumatic stress disorder, but the risks may outweigh the benefits. Erika Dyck, Canada research chair and professor in history of health and social justice at the University of Saskatchewan Psychedelics may conjure images of beatniks, hippies and Deadheads, but recent […]

February 11, 2022 February 10, 2022
08:59

Head to head: Should private drug plans require biosimilar non-medical switching?

While one side highlights how plan sponsors can contribute to biosimilar sustainability, the other touts the benefits to patients and the health-care system. Durhane Wong-Rieger, president and chief executive officer, Institute for Optimizing Health Outcomes The Institute for Optimizing Health Outcomes recently published a scorecard rating the biosimilar policy frameworks of European countries across seven […]

August 13, 2021 August 11, 2021
08:59

Head to head: Should plan sponsors buy annuities via insurers or go DIY?

Two experts weigh in on the merits and drawbacks of taking the traditional annuities route versus opting for the newer do-it-yourself option. Marco Dickner, retirement risk management leader for Willis Towers Watson in Canada Although annuity purchases have become an important pension risk management option over the last decade, a countertrend is emerging for plan […]

May 14, 2021 June 2, 2021
08:59

Conference Coverage: 2020 Face to Face Drug Plan Management Forum

On Dec. 9, the 2020 Face to Face Drug Plan Management Forum featured sessions on prior authorization, Canadian drug policy issues and impacts, plan design considerations related to chronic disease and pharmacy benefits management. Here’s what you missed! Biosimilars, pharmacogenetics shaping the future of pharmacy benefits management Plan sponsors with growing concerns about benefits plan […]

January 15, 2021 July 14, 2021
09:00